Black Diamond Therapeutics, Inc.BDTXEarnings & Financial Report
Black Diamond Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted, mutation-specific therapies for genetically defined hard-to-treat cancers with limited existing treatment options. Its pipeline targets rare oncogenic driver alterations across multiple solid tumor types to serve underserved global patient populations.
BDTX Q4 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-17.6M
Net Profit
$-15.1M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.25
Black Diamond Therapeutics, Inc. Q4 FY2025 Financial Summary
Black Diamond Therapeutics, Inc. reported revenue of $0 for Q4 FY2025, with a net profit of $-15.1M (up 5.4% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-15.1M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Black Diamond Therapeutics, Inc. Annual Revenue by Year
Black Diamond Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $70.0M).
Black Diamond Therapeutics, Inc. Quarterly Revenue & Net Profit History
Black Diamond Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $-15.1M | N/A |
| Q3 FY2025 | $0 | — | $-8.5M | N/A |
| Q2 FY2025 | $0 | — | $-10.6M | N/A |
| Q1 FY2025 | $70.0M | — | $56.5M | 80.8% |
| Q4 FY2024 | $0 | — | $-16.0M | N/A |
| Q3 FY2024 | $0 | — | $-15.6M | N/A |
| Q2 FY2024 | $0 | — | $-19.9M | N/A |
| Q1 FY2024 | $0 | — | $-18.2M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $70.0M | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $142.5M | $150.0M | $137.9M | $122.6M | $176.2M | $166.4M | $157.7M | $143.0M |
| Liabilities | $38.2M | $39.0M | $40.5M | $39.4M | $34.7M | $33.8M | $31.6M | $30.8M |
| Equity | $104.3M | $110.5M | $97.4M | $83.3M | $141.5M | $132.6M | $126.2M | $112.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-21.2M | $-14.7M | $-11.3M | $-15.1M | $53.4M | $-9.2M | $-7.8M | $-6.8M |